Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
Sponsor: Qilu Pharmaceutical Co., Ltd.
Summary
Efficacy and Safety Study of QLM3004 in Myopic Children
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Different Concentrations of QLM3004 in Delaying the Progression of Myopia in Children
Key Details
Gender
All
Age Range
6 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
735
Start Date
2023-08-20
Completion Date
2027-06
Last Updated
2023-11-30
Healthy Volunteers
No
Conditions
Interventions
QLM3004 Concentration 1
Low dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime
QLM3004 Concentration 2
Medium dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime
QLM3004 Concentration 3
High dose of QLM3004 Ophthalmic Solution 1 drop in each eye at bedtime
Placebo
Vehicle
Locations (1)
The Affiliated Eye Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China